var quiz = [
  {
    q: `Identification of patients with high-risk prostate cancer is best achieved by:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->transrectal ultrasonography.`,
      `<!--b. -->serum prostate-specific antigen (PSA).`,
      `<!--c. -->digital rectal examination.`,
      `<!--d. -->serum PSA, biopsy grade, clinical stage.`,
      `<!--e. -->PSA kinetics.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [3],
    ansText: `Rationale: Although clinical stage, serum PSA, and Gleason score all individually predict pathologic stage and prognosis, the combination of these three variables increases the accuracy of this assessment.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
  },
  {
    q: `By using the Kattan postoperative nomogram, which of the following contributes most to the risk of biochemical recurrence after radical prostatectomy?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Positive surgical margin`,
      `<!--b. -->Pretreatment serum PSA of 17 ng/mL`,
      `<!--c. -->Gleason 4 + 3 disease`,
      `<!--d. -->Established capsular penetration`,
      `<!--e. -->Seminal vesicle invasion`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: <b>Despite the trend toward lower serum PSA at the time of diagnosis, PSA remains an important predictor of treatment failure, and greater elevations (&gt;8 ng/mL) of PSA contribute significantly to calculated biochemical recurrence.</b>`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },
  {
    q: `Neoadjuvant androgen deprivation (AD) before radical prostatectomy leads to:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->improved biochemical-free survival.`,
      `<!--b. -->improved overall survival.`,
      `<!--c. -->reduced positive surgical margins.`,
      `<!--d. -->reduced local recurrence.`,
      `<!--e. -->increased operative morbidity.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: <b>The randomized and nonrandomized studies of neoadjuvant androgen deprivation in men with lower clinical stage (cT1-T2) clearly demonstrate a reduction in the rate of positive surgical margins; however, this advantage has not been observed in men with cT3c and has not translated into improved long-term PSA-free survival.</b>`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },
  {
    q: `In men with locally advanced prostate cancer undergoing prostatectomy, clinical overstaging (i.e., pathologically organ confined disease) occurs in:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->less than 10%.`,
      `<!--b. -->15% to 30%.`,
      `<!--c. -->40% to 60%.`,
      `<!--d. -->70% to 80%.`,
      `<!--e. -->more than 90%.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: Recent data suggest that clinical overstaging occurs in approximately 27% of men with clinical stage T3 disease undergoing prostatectomy, consistent with the range in the literature of 7% to 26%.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `The use of high-dose antiandrogen monotherapy after prostatectomy in men with locally advanced disease:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->reduces disease progression.`,
      `<!--b. -->increases cardiac morbidity.`,
      `<!--c. -->does not have an impact on sexual function.`,
      `<!--d. -->improves overall survival.`,
      `<!--e. -->improves local disease control.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: Bicalutamide at greater dose (150 mg) appears to have a positive effect in those men with locally advanced disease, with 43% reduction in disease progression and potential benefit of improved survival; however, it should be remembered that high-dose bicalutamide given to men with localized prostate cancer is associated with increased risk of death (hazard ratio: 1.23).`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },
  {
    q: `In men with locally advanced/high-risk prostate cancer, the most effective treatment among the following options is:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->brachytherapy + external-beam radiation therapy.`,
      `<!--b. -->neoadjuvant AD + external-beam radiation therapy.`,
      `<!--c. -->neoadjuvant AD + external-beam radiation therapy + adjuvant AD.`,
      `<!--d. -->concurrent AD plus external-beam radiation therapy.`,
      `<!--e. -->long-term AD alone.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: <b>The accumulated data from multiple Radiation Therapy Oncology Group (RTOG) and European Organisation for Research and Treatment of Cancer (EORTC) trials suggest that improved outcomes are achieved with greater duration of administration of androgen deprivation in combination with external-beam radiation therapy, with apparent benefit of both neoadjuvant and adjuvant therapy.</b>`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `Risk assessment schemes for prostate cancer are most accurate for patients with:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->low-risk disease.`,
      `<!--b. -->high-risk disease.`,
      `<!--c. -->the disease.`,
      `<!--d. -->metastatic disease.`,
      `<!--e. -->locally advanced cancers.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: Validation has confirmed the general accuracy of the available risk assessment tools, but there is a tendency to overestimate the risk of cancer recurrence in men with high-risk disease features.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `The current appropriate dose for adjuvant radiation therapy after radical prostatectomy is:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->less than 45 Gy.`,
      `<!--b. -->45 to 50 Gy.`,
      `<!--c. -->51 to 55 Gy.`,
      `<!--d. -->56 to 60 Gy.`,
      `<!--e. -->greater than 60 Gy.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: There is a trend to improve response to adjuvant radiation therapy, and most contemporary series report doses greater than 60 Gy, with potential threshold of either 61.2 or 64 Gy. Similarly, for primary radiation therapy, improved outcomes have been shown for higher doses (78 Gy or greater).`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
    type: `MCSS`,
  },
  {
    q: `The use of AD in combination with radiation therapy for those with high-risk cancers is associated with all of the following EXCEPT:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->improved local control.`,
      `<!--b. -->improved biochemical-free survival.`,
      `<!--c. -->less gastrointestinal toxicity.`,
      `<!--d. -->worsened sexual function.`,
      `<!--e. -->more urinary frequency.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: The longer application (longer than 6 to 9 months) of AD in conjunction with radiation therapy may be associated with increased rectal morbidity as well as sexual dysfunction.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `The benefits of early radiation therapy after radical prostatectomy in men with locally advanced disease are observed:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->for improved local control.`,
      `<!--b. -->for improved overall survival.`,
      `<!--c. -->in men with positive surgical margins.`,
      `<!--d. -->none of the above.`,
      `<!--e. -->all of the above.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: <b>Data from EORTC 22911 and Southwest Oncology Group (SWOG) 8794 clearly demonstrate a benefit of adjuvant radiation therapy in men with pT3 disease, after radical prostatectomy, with respect to biochemical relapse-free, metastasis-free, and overall survival, as well as improved local control.</b> The EORTC study suggests that patients who benefit the most are those with positive surgical margins.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `After radical prostatectomy in those with loco-regional disease, overall survival may be optimized by adjuvant treatment with:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->androgen deprivation.`,
      `<!--b. -->radiation therapy.`,
      `<!--c. -->sipuleucel-T.`,
      `<!--d. -->docetaxel.`,
      `<!--e. -->radiation therapy + androgen deprivation.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: <b>The traditional approach to those patients with N+ disease after radical prostatectomy has been androgen deprivation therapy, based on results from ECOG 3886 showing improved overall survival for immediate versus delayed treatment.</b> More recent studies suggest that the combination of androgen deprivation and radiotherapy may yield the best outcomes with respect to overall survival, even when compared with androgen deprivation alone. There is no evidence that adjuvant immunotherapy or chemotherapy improves outcomes in these patients after surgery.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `Over the past decade, the trend in the treatment of men with higher-risk disease (CAPRA 6-10) has shown:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->increase in primary androgen deprivation.`,
      `<!--b. -->decrease in primary androgen deprivation.`,
      `<!--c. -->increase in radiation therapy.`,
      `<!--d. -->decrease in radical prostatectomy.`,
      `<!--e. -->decrease in active surveillance/watchful waiting.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: <b>There has been significant evolution in the management of high-risk prostate cancer.</b> A contemporary analysis of the CaPSURE database has shown a significant increase in the number of men undergoing radical prostatectomy with concomitant decrease in primary androgen deprivation as well as radiation therapy. Rates of surveillance/watchful waiting appear stable.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<b>Imaging</b> A 65-year-old man underwent a radical retropubic prostatectomy 4 years ago for a pT3a N0 Gleason 8 adenocarcinoma of the prostate. Two years postoperatively, his PSA first became detectable and has slowly risen since then to its current value of 1.2 ng/mL. A computed tomography (CT) scan of the pelvis is obtained and is depicted in <a class="lightboxcallout" img-ref="image_fig_159_1" href="b39cea5ea5144c4bb16e59e1ed4d65ad">Fig. 159.1</a>. The most likely diagnosis is:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->retained seminal vesicle.`,
      `<!--b. -->enlarged lymph node.`,
      `<!--c. -->recurrence in the prostatectomy bed.`,
      `<!--d. -->rectal mass.`,
      `<!--e. -->rectal diverticulum.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: The pelvic CT scan demonstrates a mass in the prostatectomy bed on the right at the level of the urethra-vesicle anastomosis. Because the mass is anterior to the rectum, it is not likely to be a lymph node or seminal vesicle. In view of the radical prostatectomy specimen and the rising PSA, the mass is likely a prostate cancer recurrence in the prostatectomy bed.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
];
